Arbutus Biopharma Corp share price logo

Arbutus Biopharma Corp

NASDAQ: ABUS

Small Cap

$4.39

(+0.11%)

as on

Arbutus Biopharma Corp Stock Performance

as on May 6, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $4.35
    $4.54
    downward going graph

    0.91%

    Downside

    3.42%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $2.94
    $5.10
    downward going graph

    33.03%

    Downside

    16.17%

    Upside

    downward going graph

Arbutus Biopharma Corp share price movements today

Previous Close
$4.39
Open
$4.44
Volume
383.5K
Day's Low - High
$4.35 - $4.54
52 Week Low - High
$2.94 - $5.10

Arbutus Biopharma Corp Historical Returns

1 Month Return
-1.57 %
3 Month Return
+ 14.32 %
1 Year Return
+ 32.23 %
3 Year Return
+ 68.85 %
5 Year Return
+ 56.79 %

Arbutus Biopharma Corp Stock Fundamentals & Key Indicators

Check Arbutus Biopharma Corp market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$850.8M

EPS (TTM)

-0.227

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-26.7M

Revenue (TTM)

14.1M

Profit Margin

-237.88%

Return On Equity TTM

-38.52%

Arbutus Biopharma Corp vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Arbutus Biopharma Corp with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Arbutus Biopharma Corp image
Arbutus Biopharma Corp
BUY$850.8M56.79%NA-237.88%
Alnylam Pharmaceuticals Inc image
Alnylam Pharmaceuticals Inc
BUY$39.8B125.53%74.6712.55%
Vertex Pharmaceuticals Inc image
Vertex Pharmaceuticals Inc
BUY$109.3B101.66%27.732.94%
BeiGene, Ltd. image
BeiGene, Ltd.
NA$33.0BNA118.865.37%
Regeneron Pharmaceuticals Inc image
Regeneron Pharmaceuticals Inc
BUY$73.5B42.22%17.1229.65%

Stock Returns calculator for Arbutus Biopharma Corp Stock including INR - Dollar returns

The Arbutus Biopharma Corp stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Arbutus Biopharma Corp investment value today

Current value as on today

₹1,49,461

Returns

₹49,461

(+49.46%)

Returns from Arbutus Biopharma Corp Stock

₹32,229 (+32.23%)

Dollar Impact

₹17,232 (+17.23%)

Analyst Recommendation on Arbutus Biopharma Corp Stock

Based on 11 analysts

BUY

81.82%

Buy

18.18%

Hold

0.00%

Sell

Based on 11 analysts, 81.82% of analysts recommend a 'BUY' rating for Arbutus Biopharma Corp. Average target price of $5.25

Arbutus Biopharma Corp Share Price Target

Get share price movements and forecasts by analysts on Arbutus Biopharma Corp.

What analysts predicted

16.38%UPSIDE

Target Price

$5.25

Current Price

$4.39

Analyzed by

11 Analysts

Target

$5.25

Arbutus Biopharma Corp target price $5.25, a slight upside of 16.38% compared to current price of $4.39. According to 11 analysts rating.

Arbutus Biopharma Corp Stock’s Investor Sentiment and Interest

Search interest for Arbutus Biopharma Corp Stock has increased by 40% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:40% versus previous 30 day period

Arbutus Biopharma Corp Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
4
2
1
1
1
1
1
10
0
1
Gross Profit
4
-15
1
1
1
-7
-7
10
0
1
Operating Income
-21
-20
-19
-21
-21
-13
-34
1
-8
-7
EBITDA
-19
-20
-17
-19
-19
-15
-24
2
-7
-7
Interest Expense
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-20
-19
-17
-19
-19
-12
-24
2
-7
-3
Income Tax Expense
0
1
0
0
-
-
-
-
-
-
Net Income
-20
-19
-17
-19
-19
-12
-24
2
-7
-3
Net Profit Margin
-431.60%
-900.33%
-1166.78%
-1146.93%
-1472.52%
-796.19%
-1390.36%
23.49%
-1463.52%
-357.37%

Arbutus Biopharma Corp Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
1
10
5
6
6
10
39
18
6
14
Gross Profit
-59
-52
-52
-51
-40
10
39
18
6
13
Operating Income
-491
-110
-89
-143
-57
-73
-65
-78
-76
-27
EBITDA
-488
-106
-58
-162
-57
-71
-61
-70
-68
-26
Interest Expense
1
0
0
2
4
2
1
0
0
0
Depreciation
-
2
2
2
1
1
1
1
1
0
Income Before Tax
-489
-108
-61
-166
-63
-76
-65
-72
-69
-33
Income Tax Expense
-105
-24
-4
-12
1
1
4
0
-
-
Net Income
-384
-84
-57
-153
-63
-76
-69
-72
-69
-33
Net Profit Margin
-25606.67%
-788.79%
-967.80%
-2557.36%
-921.97%
-693.91%
-178.01%
-401.57%
-1133.04%
-237.88%

Arbutus Biopharma Corp Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-19
-17
-19
-19
-12
-24
2
-7
-3
Operating Cash Flow
-17
-19
-14
-20
-10
-13
-15
-5
-4
Investing Cash Flow
22
11
9
-11
13
11
15
-10
-1
Financing Cash Flow
3
24
24
1
1
2
0
0
1
Change in Cash
8
16
19
-30
4
0
0
-15
-4

Arbutus Biopharma Corp Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-84
-57
-153
-63
-76
-69
-72
-69
-33
Operating Cash Flow
-48
-67
-71
-51
-67
-35
-85
-64
-39
Investing Cash Flow
27
-4
28
-14
-12
-74
50
22
15
Financing Cash Flow
49
55
37
86
137
31
30
51
5
Change in Cash
30
-17
-5
20
57
-78
-4
10
-18

Global Institutional Holdings in Arbutus Biopharma Corp

Funds
Holdings
BlackBarn Capital Partners LP
0.94%
BMO Capital Markets Corp.
0.39%
State Street Corp
2.08%
The Goldman Sachs Group Inc
1.13%
Vanguard Group Inc
4.69%
See all

Insights on Arbutus Biopharma Corp

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, ABUS has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -7.74M → -3.75M (in $), with an average increase of 106.1% per quarter

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, ABUS has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, ABUS stock has moved up by 5.8%

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 529.0K → 1.05M (in $), with an average increase of 49.7% per quarter

About Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
OrganisationArbutus Biopharma Corp
Headquarters701 Veterans Circle, Warminster, PA, United States, 18974
IndustryBiotechnology
CEOMs. Lindsay Androski J.D., M.B.A.
E-voting on sharesClick here to vote

Key Management of Arbutus Biopharma Corp

Name

Title

Ms. Lindsay Androski J.D., M.B.A.

President, CEO & Chairman

Mr. Tuan Nguyen

Chief Financial Officer

Mr. Andrew J. Sung

General Counsel

Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C.

Corporate Secretary

FAQs

What is Arbutus Biopharma Corp share price today?

Arbutus Biopharma Corp share price today is $4.39 as on at the close of the market. Arbutus Biopharma Corp share today touched a day high of $4.54 and a low of $4.35.

What is the 52 week high and 52 week low for Arbutus Biopharma Corp share?

Arbutus Biopharma Corp share touched a 52 week high of $5.1 on and a 52 week low of $2.94 on . Arbutus Biopharma Corp stock price today i.e. is closed at $4.39,which is 13.92% down from its 52 week high and 49.32% up from its 52 week low.

What is Arbutus Biopharma Corp's market capitalisation today?

Arbutus Biopharma Corp market capitalisation is $0.00T as on .

How to invest in Arbutus Biopharma Corp Stock (ABUS) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Arbutus Biopharma Corp on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Arbutus Biopharma Corp Shares that will get you 0.3417 shares as per Arbutus Biopharma Corp share price of $4.39 per share as on May 6, 2026 at 1:29 am IST.

What is the minimum amount required to buy Arbutus Biopharma Corp Stock (ABUS) from India?

Indian investors can start investing in Arbutus Biopharma Corp (ABUS) shares with as little as ₹95.28 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹952.80 in Arbutus Biopharma Corp stock (as per the Rupee-Dollar exchange rate as on ). Based on Arbutus Biopharma Corp share’s latest price of $4.39 as on May 6, 2026 at 1:29 am IST, you will get 2.2779 shares of Arbutus Biopharma Corp. Learn more about fractional shares .

What are the returns that Arbutus Biopharma Corp has given to Indian investors in the last 5 years?

Arbutus Biopharma Corp stock has given 56.79% share price returns and 28.83% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?